Ablynx aims to launch llama-based arthritis drug in 2013

01/26/2010 | Reuters

Ablynx CEO Edwin Moses said the Belgian company expects to launch its first llama-derived nanomedicine as early as 2013 through a partnership with Pfizer. The drug, which was developed from extra-small antibodies from llamas, could replace Pfizer's Enbrel as a blockbuster treatment for rheumatoid arthritis.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director Medical Affairs
Edwards Lifesciences
Irvine, CA
Senior Scientist - Cell Engineering Group
Pfizer
San Francisco, CA
Medical Director - Physician
Willamette Valley Community Health
Salem, OR
Area Reimbursement Manager (CT, MA, MD, ME, NH, NJ, NY, PA, VT)
SI-BONE, INC
Multiple Locations, SL_Multiple Locations
Medical Director - Physician
Willamette Valley Community Health
Salem, OR